Kibow Biotech Inc. to Support 4th Annual Kidney Patient Summit (March 6th & 7th) and World Kidney Day (March 9th) With Its Independent Educational Webinar on "Obesity and Chronic Kidney Disease" in Modulating the "Gut Microbiome with Pro/Prebiotics" Based on Its Novel "Enteric Dialysis®" Technology

NEWTOWN SQUARE, Pa., March 6, 2017 /PRNewswire/ -- The 4^th annual Kidney Patient Summit is to be held on March 6^th and 7^th in Washington DC. At this unique event, nearly 150 advocates from six different kidney disease organizations around the country will converge on Capitol Hill, to meet personally with lawmakers and put a human face on kidney disease. This largest event to date brings together, in a unified voice, NKF's Kidney Advocacy Committee members and advocates from six other kidney disease foundations/organizations.  Their main message to the law makers - "My Kidneys, My Life" Mantra - is aimed to push priorities on early detection, living organ donation, and more funding to battle kidney disease (http://www.prnewswire.com/news-releases/advocates-across-us-to-bring-my-kidneys-my-life-mantra-to-washington-dc-for-4th-annual-kidney-patient-summit-300416773.html).

Coincidentally, the yearly event World Kidney Day is also scheduled a day later on March 9^th. "World Kidney Day aims to raise awareness of the importance of our kidneys to our overall health and to reduce the frequency and impact of kidney disease and its associated health problems worldwide. World Kidney Day comes back every year. All across the globe many hundred events take place from public screenings in Argentina to Zumba marathons in Malaysia. We do it all to create awareness.  Awareness about preventive behaviors, awareness about risk factors, and awareness about how to live with a kidney disease. We do this because we want kidney health for all (For more information, please refer to http://www.worldkidneyday.org/about/world-kidney-day/ )".

Kibow Biotech, Inc. is pleased to join dual national and global awareness campaign with an educational webinar titled "Obesity and Kidney Disease".  The live webinar will be on March 7th at 2:00 pm ET and is presented through our sponsored educational partnership with "Integrative Practitioner".  Subsequently the on demand podcast will be made available beginning March 9th for an additional 30 days.  This webinar will provide an overview of the global epidemic of obesity and its causal relationship to various diseases that often ultimately lead to renal failure. (To view and listen to this live educational webinar, please register https://www.integrativepractitioner.com/educational-sponsors/obesity-and-kidney-disease/ . Even if you are unable to attend, please register. Only those registered can access the podcast at your convenience on a later date and time.)

Focusing specifically on the Gut-Kidney axis, these webinar speakers will detail how modulation of the gut microbiome with targeted, clinically developed and validated probiotic & prebiotic (synbiotics) to address Dysbiosis can help to promote and maintain healthy kidney function.

They will introduce "Enteric Dialysis®", an enteric toxin reduction technology that promotes metabolization and removal of various uremic toxins via the gut.

The company's extensive scientific (R&D) and clinical data from three different pilot/observational scientific human clinical trials have been published in peer reviewed scientific/medical journals (http://www.kibowbiotech.com/rd/).

The probiotic microbial strains used in the product formulation are "Generally Recognized as Safe" (GRAS status), according to the regulations of U.S. FDA. The company is also exploring the option of conducting additional large scale multi-site human clinical trials on persons afflicted with CKD III/IV (pre-dialysis) stages. Subject to positive outcomes towards improving kidney function; these additional human clinical trials will help gain greater recognition and acceptance by consumers and healthcare professionals worldwide.  

About Uremic Toxin Reduction Technology – Also known as "Enteric Dialysis®": Kibow's novel "uremic toxin removal technology" addresses the diffusion of various uremic toxins into the bowel as a consequence of failing kidney function. The Company's patented and proprietary dietary supplements, Renadyl™ (for CKD patients) and Azodyl® for cats and dogs with moderate to severe kidney failure (a veterinary formulation licensed to Vetoquinol http://www.vetoquinolusa.com/) consists of a combination of three specific probiotic microbial strains and chosen prebiotics.

Forward-looking statements: This press release contains forward-looking statements that reflect management's current views of future events, including the status of proposed conducting additional large scale multi-site human clinical trials on persons afflicted with CKD III/IV (pre-dialysis) stages.  Although a dietary supplement, the Renadyl™ product formulation has been developed with a pharma like validation. Additional clinical trials and documenting the products efficacy could potentially poise for a medical reimbursement like prenatal Vitamins and enteral nutritional supplement products. The strategy is to seek medical reimbursement development of the dietary supplement formulation, Renadyl™, for kidney health in the USA and the possibility of its approval as a drug in some other countries according to respective governmental authorities. Kibow is not a pharmaceutical company. Kibow products are not drugs and may not be considered as a treatment or a therapy. The dietary supplement formulation of Renadyl™ will not cure, prevent or mitigate any disease. Actual results may differ significantly from the above forward-looking statements due to a number of factors including but not limited to the possibility that Renadyl™ may not prove to be safe or show evidence of clinical activity in each and every individuals due to various environmental or genetic factors. Other factors that could cause or contribute to differences in actual results include, but are not limited to, whether or not the Company or any of its collaborators will be able to develop drug pathway using the technologies of the Company, whether the cash resources of the Company will be sufficient to fund operations as planned; reliance on key employees, especially senior management; the uncertainty of the Company's future access to capital; the risk that the Company may not secure or maintain relationships with collaborators, and the Company's dependence on intellectual property. The Company expressly disclaims any intent or obligation to update these forward-looking statements except as required by law.

Investor & Media Contact:

N. Ranganathan
(610) 353-5130 or Email: [email protected]

SOURCE Kibow Biotech, Inc

Related Links

http://www.kibowbiotech.com